Gain Therapeutics, Inc. (GANX)

Gain Therapeutics Statistics

Total Valuation

GANX has a market cap or net worth of $93.85 million. The enterprise value is $83.34 million.

Market Cap	93.85M
Enterprise Value	83.34M

Important Dates

The last earnings date was Wednesday, November 12, 2025, before market open.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

GANX has 38.46 million shares outstanding. The number of shares has increased by 54.44% in one year.

Current Share Class	38.46M
Shares Outstanding	38.46M
Shares Change (YoY)	+54.44%
Shares Change (QoQ)	+15.35%
Owned by Insiders (%)	3.48%
Owned by Institutions (%)	11.49%
Float	37.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	14.67
P/TBV Ratio	15.80
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.52, with a Debt / Equity ratio of 0.10.

Current Ratio	2.52
Quick Ratio	2.30
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -261.72% and return on invested capital (ROIC) is -135.80%.

Return on Equity (ROE)	-261.72%
Return on Assets (ROA)	-86.79%
Return on Invested Capital (ROIC)	-135.80%
Return on Capital Employed (ROCE)	-258.68%
Revenue Per Employee	n/a
Profits Per Employee	-$775,670
Employee Count	25
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, GANX has paid $1.30 million in taxes.

Income Tax	1.30M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.49% in the last 52 weeks. The beta is 0.07, so GANX's price volatility has been lower than the market average.

Beta (5Y)	0.07
52-Week Price Change	+7.49%
50-Day Moving Average	2.94
200-Day Moving Average	2.09
Relative Strength Index (RSI)	38.72
Average Volume (20 Days)	2,126,904

Short Selling Information

The latest short interest is 2.07 million, so 5.39% of the outstanding shares have been sold short.

Short Interest	2.07M
Short Previous Month	1.26M
Short % of Shares Out	5.39%
Short % of Float	5.58%
Short Ratio (days to cover)	1.71

Income Statement

Revenue	n/a
Gross Profit	-8.95M
Operating Income	-17.59M
Pretax Income	-18.10M
Net Income	-19.39M
EBITDA	-17.55M
EBIT	-17.59M
Earnings Per Share (EPS)	-$0.64

Balance Sheet

The company has $8.81 million in cash and $605,278 in debt, with a net cash position of $8.20 million or $0.21 per share.

Cash & Cash Equivalents	8.81M
Total Debt	605,278
Net Cash	8.20M
Net Cash Per Share	$0.21
Equity (Book Value)	5.91M
Book Value Per Share	0.16
Working Capital	6.35M

Cash Flow

In the last 12 months, operating cash flow was -$17.30 million and capital expenditures -$945, giving a free cash flow of -$17.30 million.

Operating Cash Flow	-17.30M
Capital Expenditures	-945
Free Cash Flow	-17.30M
FCF Per Share	-$0.45

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GANX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-54.44%
Shareholder Yield	-54.44%
Earnings Yield	-21.18%
FCF Yield	-18.90%

Analyst Forecast

The average price target for GANX is $8.00, which is 227.87% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.00
Price Target Difference	227.87%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2